Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study

Ming Shyan Lin; Ya Chi Tu; Yu Sheng Lin; Meng Hung Lin; Chun-Liang Lin; Ming Horng Tsai; Yung Yu Hsieh; Tien Hsing Chen; Mei Yen Chen; Chung Sheng Shi

doi:10.1177/20406223241302719

Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study

Ming Shyan Lin, Ya Chi Tu, Yu Sheng Lin, Meng Hung Lin, Chun-Liang Lin, Ming Horng Tsai, Yung Yu Hsieh, Tien Hsing Chen, Mei Yen Chen, Chung Sheng Shi^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

Abstract

BACKGROUND: Hepatosteatosis is a common condition that can lead to cirrhosis and liver cancer. Galectin-3 (GAL-3) has been implicated in liver fibrosis and inflammation.

OBJECTIVES: The purpose of this study was to investigate the association between GAL-3 and hepatosteatosis.

DESIGN: This study is a retrospective secondary analysis of data from a community health screening program.

METHODS: A total of 766 participants were included in the final analysis. Hepatosteatosis was diagnosed using ultrasonography, and GAL-3 levels were measured using enzyme-linked immunosorbent assay. Logistic regression analysis was used to examine the association between GAL-3 levels and the presence of hepatosteatosis, adjusting for age, sex, and other potential confounding factors.

RESULTS: The prevalence of moderate-to-severe hepatosteatosis in the study population was 31.5%. The participants with hepatosteatosis had a significantly higher mean level of GAL-3 compared to those without hepatosteatosis (16.6 ± 7.3 vs 13.5 ± 7.3 ng/ml; p < 0.001). After adjusting for age, sex, body mass index, and other potential confounding factors, a higher level of GAL-3 was significantly associated with an increased risk of moderate-to-severe hepatosteatosis (adjusted odds ratio (aOR) 1.24, 95% confidence interval (CI) 1.05-1.46, p = 0.010). The coexistence of alanine transaminase/aspartate transaminase ratio >1 and GAL-3 >14.4 ng/ml was associated with a significantly increased risk (aOR 3.37, 95% CI: 1.90-5.99, p < 0.001).

CONCLUSION: Our findings suggest that GAL-3 level is significantly associated with the presence of moderate-to-severe hepatosteatosis, independent of other known cardiometabolic risk factors.

Original language	English
Pages (from-to)	20406223241302719
Journal	Therapeutic Advances in Chronic Disease
Volume	15
DOIs	https://doi.org/10.1177/20406223241302719
State	Published - 01 01 2024

Bibliographical note

Keywords

ALT/AST ratio
galectin-3
hepatosteatosis
metabolic syndrome
waist-to-height ratio

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/20406223241302719

Cite this

@article{32da7da76f224cdba68f10e8ae91a06b,

title = "Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study",

abstract = "BACKGROUND: Hepatosteatosis is a common condition that can lead to cirrhosis and liver cancer. Galectin-3 (GAL-3) has been implicated in liver fibrosis and inflammation.OBJECTIVES: The purpose of this study was to investigate the association between GAL-3 and hepatosteatosis.DESIGN: This study is a retrospective secondary analysis of data from a community health screening program.METHODS: A total of 766 participants were included in the final analysis. Hepatosteatosis was diagnosed using ultrasonography, and GAL-3 levels were measured using enzyme-linked immunosorbent assay. Logistic regression analysis was used to examine the association between GAL-3 levels and the presence of hepatosteatosis, adjusting for age, sex, and other potential confounding factors.RESULTS: The prevalence of moderate-to-severe hepatosteatosis in the study population was 31.5%. The participants with hepatosteatosis had a significantly higher mean level of GAL-3 compared to those without hepatosteatosis (16.6 ± 7.3 vs 13.5 ± 7.3 ng/ml; p < 0.001). After adjusting for age, sex, body mass index, and other potential confounding factors, a higher level of GAL-3 was significantly associated with an increased risk of moderate-to-severe hepatosteatosis (adjusted odds ratio (aOR) 1.24, 95% confidence interval (CI) 1.05-1.46, p = 0.010). The coexistence of alanine transaminase/aspartate transaminase ratio >1 and GAL-3 >14.4 ng/ml was associated with a significantly increased risk (aOR 3.37, 95% CI: 1.90-5.99, p < 0.001). CONCLUSION: Our findings suggest that GAL-3 level is significantly associated with the presence of moderate-to-severe hepatosteatosis, independent of other known cardiometabolic risk factors.",

keywords = "ALT/AST ratio, galectin-3, hepatosteatosis, metabolic syndrome, waist-to-height ratio",

author = "Lin, {Ming Shyan} and Tu, {Ya Chi} and Lin, {Yu Sheng} and Lin, {Meng Hung} and Chun-Liang Lin and Tsai, {Ming Horng} and Hsieh, {Yung Yu} and Chen, {Tien Hsing} and Chen, {Mei Yen} and Shi, {Chung Sheng}",

note = "{\textcopyright} The Author(s), 2024.",

year = "2024",

month = jan,

day = "1",

doi = "10.1177/20406223241302719",

language = "英语",

volume = "15",

pages = "20406223241302719",

journal = "Therapeutic Advances in Chronic Disease",

issn = "2040-6223",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study

AU - Lin, Ming Shyan

AU - Tu, Ya Chi

AU - Lin, Yu Sheng

AU - Lin, Meng Hung

AU - Lin, Chun-Liang

AU - Tsai, Ming Horng

AU - Hsieh, Yung Yu

AU - Chen, Tien Hsing

AU - Chen, Mei Yen

AU - Shi, Chung Sheng

PY - 2024/1/1

Y1 - 2024/1/1

N2 - BACKGROUND: Hepatosteatosis is a common condition that can lead to cirrhosis and liver cancer. Galectin-3 (GAL-3) has been implicated in liver fibrosis and inflammation.OBJECTIVES: The purpose of this study was to investigate the association between GAL-3 and hepatosteatosis.DESIGN: This study is a retrospective secondary analysis of data from a community health screening program.METHODS: A total of 766 participants were included in the final analysis. Hepatosteatosis was diagnosed using ultrasonography, and GAL-3 levels were measured using enzyme-linked immunosorbent assay. Logistic regression analysis was used to examine the association between GAL-3 levels and the presence of hepatosteatosis, adjusting for age, sex, and other potential confounding factors.RESULTS: The prevalence of moderate-to-severe hepatosteatosis in the study population was 31.5%. The participants with hepatosteatosis had a significantly higher mean level of GAL-3 compared to those without hepatosteatosis (16.6 ± 7.3 vs 13.5 ± 7.3 ng/ml; p < 0.001). After adjusting for age, sex, body mass index, and other potential confounding factors, a higher level of GAL-3 was significantly associated with an increased risk of moderate-to-severe hepatosteatosis (adjusted odds ratio (aOR) 1.24, 95% confidence interval (CI) 1.05-1.46, p = 0.010). The coexistence of alanine transaminase/aspartate transaminase ratio >1 and GAL-3 >14.4 ng/ml was associated with a significantly increased risk (aOR 3.37, 95% CI: 1.90-5.99, p < 0.001). CONCLUSION: Our findings suggest that GAL-3 level is significantly associated with the presence of moderate-to-severe hepatosteatosis, independent of other known cardiometabolic risk factors.

AB - BACKGROUND: Hepatosteatosis is a common condition that can lead to cirrhosis and liver cancer. Galectin-3 (GAL-3) has been implicated in liver fibrosis and inflammation.OBJECTIVES: The purpose of this study was to investigate the association between GAL-3 and hepatosteatosis.DESIGN: This study is a retrospective secondary analysis of data from a community health screening program.METHODS: A total of 766 participants were included in the final analysis. Hepatosteatosis was diagnosed using ultrasonography, and GAL-3 levels were measured using enzyme-linked immunosorbent assay. Logistic regression analysis was used to examine the association between GAL-3 levels and the presence of hepatosteatosis, adjusting for age, sex, and other potential confounding factors.RESULTS: The prevalence of moderate-to-severe hepatosteatosis in the study population was 31.5%. The participants with hepatosteatosis had a significantly higher mean level of GAL-3 compared to those without hepatosteatosis (16.6 ± 7.3 vs 13.5 ± 7.3 ng/ml; p < 0.001). After adjusting for age, sex, body mass index, and other potential confounding factors, a higher level of GAL-3 was significantly associated with an increased risk of moderate-to-severe hepatosteatosis (adjusted odds ratio (aOR) 1.24, 95% confidence interval (CI) 1.05-1.46, p = 0.010). The coexistence of alanine transaminase/aspartate transaminase ratio >1 and GAL-3 >14.4 ng/ml was associated with a significantly increased risk (aOR 3.37, 95% CI: 1.90-5.99, p < 0.001). CONCLUSION: Our findings suggest that GAL-3 level is significantly associated with the presence of moderate-to-severe hepatosteatosis, independent of other known cardiometabolic risk factors.

KW - ALT/AST ratio

KW - galectin-3

KW - hepatosteatosis

KW - metabolic syndrome

KW - waist-to-height ratio

UR - http://www.scopus.com/inward/record.url?scp=85211152157&partnerID=8YFLogxK

U2 - 10.1177/20406223241302719

DO - 10.1177/20406223241302719

M3 - 文章

C2 - 39619166

AN - SCOPUS:85211152157

SN - 2040-6223

VL - 15

SP - 20406223241302719

JO - Therapeutic Advances in Chronic Disease

JF - Therapeutic Advances in Chronic Disease

ER -

Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this